U.S. markets closed
  • S&P 500

    4,141.59
    +13.60 (+0.33%)
     
  • Dow 30

    33,677.27
    -68.13 (-0.20%)
     
  • Nasdaq

    13,996.10
    +146.10 (+1.05%)
     
  • Russell 2000

    2,228.92
    -4.86 (-0.22%)
     
  • Crude Oil

    60.50
    +0.32 (+0.53%)
     
  • Gold

    1,747.00
    -0.60 (-0.03%)
     
  • Silver

    25.42
    -0.00 (-0.00%)
     
  • EUR/USD

    1.1959
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.6230
    -0.0520 (-3.10%)
     
  • GBP/USD

    1.3760
    +0.0008 (+0.06%)
     
  • USD/JPY

    108.9190
    -0.1290 (-0.12%)
     
  • BTC-USD

    63,598.32
    +3,502.88 (+5.83%)
     
  • CMC Crypto 200

    1,353.54
    +59.55 (+4.60%)
     
  • FTSE 100

    6,890.49
    +1.37 (+0.02%)
     
  • Nikkei 225

    29,751.61
    +212.88 (+0.72%)
     

Opdivo Plus Cabometyx Combo Shows Superior Clinical Benefit Versus Sunitinib In Late-Stage Kidney Cancer Study

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) have announced updated data from Phase 3 CheckMate 9ER trial, evaluating the combination of former's Opdivo (nivolumab) and latter's Cabometyx (cabozantinib) drug compared to Pfizer Inc's (NYSE: PFE) Sutent (sunitinib) in the first-line treatment of advanced renal cell carcinoma.

  • BMY will present the data at the virtual American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium.

  • With a median follow-up of two years (23.5 months), Opdivo, combined with Cabometyx, doubled median progression-free survival (17.0 months vs. 8.3 months) compared to sunitinib, the trial's primary endpoint.

  • Almost twice as many patients responded to the combination treatment vs. sunitinib (54.8% vs. 28.4%). Opdivo plus Cabometyx demonstrated a 34% reduction in the risk of death compared to sunitinib.

  • In an exploratory analysis, the combination was associated with a disease control rate of 88.2% vs. 69.9% compared to sunitinib.

  • 6.6% of patients discontinued treatment in the combination arm due to adverse events, compared to 9.7% in Opdivo only and 7.2% discontinued in Cabometyx.

  • In a subgroup analysis of 75 patients with sarcomatoid features, the combination reduced the risk of death by 64% vs. sunitinib and demonstrating better progression-free survival (10.3 months vs. 4.2 months) and overall response rate (55.9% vs. 22.0%).

  • Price Action: In the premarket session on the last check Tuesday, EXEL shares are trading 1.4% higher at 24.45, and BMY is up 0.42% at $60.48. PFE shares are marginally higher by 0.09% at $34.85.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.